Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
about
Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancerFirst chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.Epigenetic regulation of prostate cancerIdentification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosisFunctions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Potent Inducers of Endogenous Antimicrobial Peptides for Host Directed Therapy of Infections.Epigenetic mechanisms of regulation of Foxp3 expression.Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1.First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.Entinostat for treatment of solid tumors and hematologic malignancies.Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment.4-(Cyclo-propane-carboxamido)-benzoic acid.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
P2860
Q34013315-AC3248FE-321F-4075-89A7-23A34A9F033AQ34345596-CB862862-5BD5-4BDB-B07F-4BCDEBB74B5DQ34998552-B6FA9FEC-8332-43DB-B6BB-18467CF03CBBQ35675265-C55D1ADF-BDAB-47F5-ABFB-56C1701565DBQ36001910-29415504-A392-445E-AB1B-BB0F46A70A55Q36084498-AC2FB2F1-2A64-452B-9EFF-0CB3B4EB0EF5Q36860976-0D35043F-68E2-437A-8CE8-834A328DFEC0Q37402593-B5CB7FD1-99D8-4E2C-863A-E417C9A8C5F5Q37412329-109470FE-4963-47AA-9D08-0D56F9E3D54DQ37648758-63473FAF-0F10-4F68-8621-B98DF0CA0BBCQ37660329-9CBD9A16-C2E4-474E-87A2-D00DFA1E01D5Q37925846-5BDD78A5-7794-4999-9CA0-69B074EF32F5Q38918208-65D35E84-39ED-49F3-BABD-92D50C6B74E1Q39241897-FA897128-50BD-4FF1-A592-C3A8703509ACQ39943631-53FF26F0-552B-4503-82AB-314144489AE6Q42427489-B5E42A19-8BF9-49F3-870B-B5F40E2FA8E9Q53156735-0AEDAA28-94B6-47C8-9C29-CB2F70A78AFD
P2860
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Improved synthesis of histone ...... er cells and tumor xenografts.
@ast
Improved synthesis of histone ...... er cells and tumor xenografts.
@en
type
label
Improved synthesis of histone ...... er cells and tumor xenografts.
@ast
Improved synthesis of histone ...... er cells and tumor xenografts.
@en
prefLabel
Improved synthesis of histone ...... er cells and tumor xenografts.
@ast
Improved synthesis of histone ...... er cells and tumor xenografts.
@en
P2093
P2860
P1476
Improved synthesis of histone ...... er cells and tumor xenografts.
@en
P2093
Aakanksha Khandelwal
Aashvini Belosay
Lalji K Gediya
Puranik Purushottamachar
Vincent C O Njar
P2860
P304
P356
10.1016/J.BMC.2007.12.007
P407
P577
2007-12-08T00:00:00Z